Previous 10 | Next 10 |
Sangamo Therapeutics, Inc. (SGMO) Q2 2020 Earnings Conference Call August 5, 2020 17:00 ET Company Participants McDavid Stilwell - Senior Vice President, Corporate Communication and IR Sandy Macrae - Chief Executive Officer Bettina Cockroft - Chief Medical Officer Sung Lee - Ch...
Sangamo Therapeutics (NASDAQ: SGMO ) : Q2 GAAP EPS of -$0.26 misses by $0.37 . More news on: Sangamo Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported second quarter 2020 financial results and recent business highlights. “We are very excited about our global collaboration ag...
Quick Take Freeline Therapeutics Holdings plc ( FRLN ) intends to raise $125 million from the sale of ADSs representing underlying common stock in an IPO, according to an amended registration statement . The company is advancing a pipeline of treatment candidates for hemophilia, Gaucher d...
MorphoSys receives FDA approval for Monjuvi MorphoSys AG ( MOR ) announced that the FDA has approved the use of Monjuvi in conjunction with lenalidomide, for treating adult patients suffering from relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, includ...
Sangamo Therapeutics (NASDAQ: SGMO ) will collaborate with Novartis (NYSE: NVS ) to develop and commercialize gene regulation therapies to treat neurodevelopmental conditions including autism spectrum disorder. The partnership will leverage SGMO's zinc finger protein transcription fact...
- Collaboration for gene regulation therapies for three neurodevelopmental targets, including for genes linked to autism spectrum disorder and intellectual disability - Sangamo will receive a $75M upfront licensing fee and is eligible to receive up to $720M in potential milestones, as ...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarter 2020 financial results after the market closes on Wednesday, August 5, 2020. The press release will be followed by a conference call at 5:00 ...
Quick Take Freeline Therapeutics Holdings plc ( FRLN ) has filed to raise $100 million in an IPO of its ADSs representing underlying ordinary shares, according to an F-1 registration statement . The company is a gene therapy biopharma developing treatments for hemophilia B and other serio...
Author technical setup chart Sangamo ( SGMO ) is well-situated for the remainder of 2020 after the Biogen ( BIIB ) collaboration. 1Q20 cash plus the Biogen proceeds brought available cash to over $700 million. Sangamo C20 guidance for non-GAAP operating expenses (opex less stock compensati...
News, Short Squeeze, Breakout and More Instantly...
Sangamo Therapeutics Inc. Company Name:
SGMO Stock Symbol:
NASDAQ Market:
Sangamo Therapeutics Inc. Website:
2024-05-15 13:30:05 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for SGMO on May 15, 2024 11:01AM ET. The previous analyst recommendation was Underperform. SGMO was trading at $0.5901 at issue of the analyst recommendation. The overall analyst consensus ...
Showcased 20 presentations at the 27 th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting demonstrating progression of neurology-focused preclinical pipeline, including additional data from novel delivery capsid, STAC-BBB, that demonstrated industry-leading blood-brain barrie...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing. Building on Sangamo’s deep expertise in protein-DNA interactions derived from...